Loading...
•
Jun 30, 2020
BioCryst Q2 2020 Earnings Report
BioCryst reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.
Key Takeaways
BioCryst announced Q2 2020 financial results, with total revenues of $2.9 million compared to $1.4 million in Q2 2019. Net loss for the quarter was $38.6 million, or $0.24 per share. The company's cash, cash equivalents, and investments totaled $191.6 million at the end of the quarter.
ORLADEYO approvals are expected in the U.S. and Japan in Q4 2020, and in the EU in early 2021.
Data from treatment-naïve PNH patients for BCX9930 (200 mg/400mg) is expected in Q3 2020.
Data from poor-responders to C5 inhibitors for BCX9930 (200 mg/400mg) is expected by year-end 2020.
Information from Part 1 of the galidesivir trial in COVID-19 patients is expected by the end of Q3 2020.
Forward Guidance
BioCryst expects full year 2020 net operating cash use to be in the range of $150 to $165 million, and its operating expenses to be in the range of $180 to $195 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...